VU0359595
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530613

CAS#: 1246303-14-9

Description: VU0359595, also known as ML-270 and CID-53361951, is an inhibitor of PLD1 (IC50 = 3.7 nM). Downregulation of PLD1 and exposure to the PLD1 inhibitor VU0359595 attenuated PLD activity and strongly reduced the mitogenic activity of serum and IGF-1. Phospholipase D is a target for inhibition of astroglial proliferation by ethanol.


Chemical Structure

img
VU0359595
CAS# 1246303-14-9

Theoretical Analysis

MedKoo Cat#: 530613
Name: VU0359595
CAS#: 1246303-14-9
Chemical Formula: C25H29BrN4O2
Exact Mass: 496.15
Molecular Weight: 497.437
Elemental Analysis: C, 60.36; H, 5.88; Br, 16.06; N, 11.26; O, 6.43

Price and Availability

Size Price Availability Quantity
5mg USD 350 2 Weeks
10mg USD 600 2 Weeks
Bulk inquiry

Synonym: ML-270, ML 270, ML270, VU0359595, VU-0359595, VU 0359595, CID-53361951, CID53361951, CID 53361951

IUPAC/Chemical Name: (1R,2R)-N-[(1S)-2-[4-(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-phenyl-cyclopropanecarboxamide

InChi Key: JSVNNLRZCJAYTQ-ORYQWCPZSA-N

InChi Code: InChI=1S/C25H29BrN4O2/c1-16(27-24(31)21-14-20(21)17-5-3-2-4-6-17)15-29-11-9-19(10-12-29)30-23-8-7-18(26)13-22(23)28-25(30)32/h2-8,13,16,19-21H,9-12,14-15H2,1H3,(H,27,31)(H,28,32)/t16-,20-,21+/m0/s1

SMILES Code: O=C([C@H]1[C@H](C2=CC=CC=C2)C1)N[C@@H](C)CN3CCC(N4C5=CC=C(Br)C=C5NC4=O)CC3

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 497.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Chaves-Moreira D, de Moraes FR, Caruso ÍP, Chaim OM, Senff-Ribeiro A, Ullah A, da Silva LS, Chahine J, Arni RK, Veiga SS. Potential Implications for Designing Drugs Against the Brown Spider Venom Phospholipase-D. J Cell Biochem. 2017 Apr;118(4):726-738. doi: 10.1002/jcb.25678. Epub 2016 Oct 26. PubMed PMID: 27563734.

2: Burkhardt U, Beyer S, Klein J. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. doi: 10.1016/j.ejphar.2015.05.004. Epub 2015 May 9. PubMed PMID: 25967349.

3: Burkhardt U, Wojcik B, Zimmermann M, Klein J. Phospholipase D is a target for inhibition of astroglial proliferation by ethanol. Neuropharmacology. 2014 Apr;79:1-9. doi: 10.1016/j.neuropharm.2013.11.002. Epub 2013 Nov 19. PubMed PMID: 24262632.